{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T18:40:22Z","timestamp":1787078422512,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08397"],"award-info":[{"award-number":["22K08397"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Advanced cutaneous squamous cell carcinoma (cSCC) is treated with chemotherapy and\/or radiotherapy, but these typically fail to achieve satisfactory clinical outcomes. There have been no preclinical studies to evaluate the effectiveness of eribulin against cSCC. Here, we examine the effects of eribulin using cSCC cell lines and a novel cSCC patient-derived xenograft (PDX) model. In the cSCC cell lines (A431 and DJM-1 cells), eribulin was found to inhibit tumor cell proliferation in vitro as assessed by cell ATP levels. DNA content analysis by fluorescence-activated cell sorting (FACS) showed that eribulin induced G2\/M cell cycle arrest and apoptosis. In xenograft models of cSCC cell lines, the administration of eribulin suppressed tumor growth in vivo. We also developed a cSCC patient-derived xenograft (PDX) which reproduces the histological and genetic characteristics of a primary tumor. Pathogenic mutations in\n                    <jats:italic>TP53<\/jats:italic>\n                    and\n                    <jats:italic>ARID2<\/jats:italic>\n                    were detected in the patient\u2019s metastatic tumor and in the PDX tumor. The cSCC-PDX responded well to the administration of eribulin and cisplatin. In conclusion, the present study shows the promising antineoplastic effects of eribulin in cSCC. Also, we established a novel cSCC-PDX model that preserves the patient\u2019s tumor. This PDX could assist researchers who are exploring innovative therapies for cSCC.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-35811-3","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T12:02:01Z","timestamp":1685188921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft"],"prefix":"10.1038","volume":"13","author":[{"given":"Che-Yuan","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodai","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Tokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ujiie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"key":"35811_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","volume":"78","author":"SKT Que","year":"2018","unstructured":"Que, S. K. T., Zwald, F. O. & Schmults, C. D. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J. Am. Acad. Dermatol. 78, 237\u2013247. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.059 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"S1","key":"35811_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jdv.17728","volume":"36","author":"E de Jong","year":"2022","unstructured":"de Jong, E., Lammerts, M., Genders, R. E. & Bouwes Bavinck, J. N. Update of advanced cutaneous squamous cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 36(S1), 6\u201310. https:\/\/doi.org\/10.1111\/jdv.17728 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"35811_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes, J. et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 377, 914\u2013923. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6 (2011).","journal-title":"Lancet"},{"key":"35811_CR4","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.7150\/jca.35109","volume":"10","author":"L Pizzuti","year":"2019","unstructured":"Pizzuti, L. et al. Eribulin in triple negative metastatic breast cancer: Critic interpretation of current evidence and projection for future scenarios. J. Cancer 10, 5903\u20135914. https:\/\/doi.org\/10.7150\/jca.35109 (2019).","journal-title":"J. Cancer"},{"key":"35811_CR5","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Schoffski","year":"2016","unstructured":"Schoffski, P. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet 387, 1629\u20131637. https:\/\/doi.org\/10.1016\/S0140-6736(15)01283-0 (2016).","journal-title":"Lancet"},{"key":"35811_CR6","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","volume":"7","author":"T Okouneva","year":"2008","unstructured":"Okouneva, T., Azarenko, O., Wilson, L., Littlefield, B. A. & Jordan, M. A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 7, 2003\u20132011. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0095 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"35811_CR7","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/ijms20040840","volume":"20","author":"C Roma-Rodrigues","year":"2019","unstructured":"Roma-Rodrigues, C., Mendes, R., Baptista, P. V. & Fernandes, A. R. Targeting tumor microenvironment for cancer therapy. Int. J. Mol. Sci. 20, 840 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"35811_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida, T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br. J. Cancer 110, 1497\u20131505. https:\/\/doi.org\/10.1038\/bjc.2014.80 (2014).","journal-title":"Br. J. Cancer"},{"key":"35811_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nrc822","volume":"2","author":"JP Thiery","year":"2002","unstructured":"Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442\u2013454. https:\/\/doi.org\/10.1038\/nrc822 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"35811_CR10","doi-asserted-by":"publisher","first-page":"12173","DOI":"10.1002\/jcp.27955","volume":"234","author":"A Ahmadi","year":"2019","unstructured":"Ahmadi, A., Najafi, M., Farhood, B. & Mortezaee, K. Transforming growth factor-beta signaling: Tumorigenesis and targeting for cancer therapy. J. Cell. Physiol. 234, 12173\u201312187. https:\/\/doi.org\/10.1002\/jcp.27955 (2019).","journal-title":"J. Cell. Physiol."},{"key":"35811_CR11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi, Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 105, 1334\u20131342. https:\/\/doi.org\/10.1111\/cas.12488 (2014).","journal-title":"Cancer Sci."},{"key":"35811_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.21873\/anticanres.12236","volume":"38","author":"S Kashiwagi","year":"2018","unstructured":"Kashiwagi, S. et al. Mesenchymal-epithelial transition and tumor vascular remodeling in eribulin chemotherapy for breast cancer. Anticancer Res. 38, 401\u2013410. https:\/\/doi.org\/10.21873\/anticanres.12236 (2018).","journal-title":"Anticancer Res."},{"key":"35811_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.18632\/oncotarget.26536","volume":"10","author":"K Watanabe","year":"2019","unstructured":"Watanabe, K. et al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget 10, 161\u2013174. https:\/\/doi.org\/10.18632\/oncotarget.26536 (2019).","journal-title":"Oncotarget"},{"key":"35811_CR14","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1111\/cas.14067","volume":"110","author":"M Takahashi","year":"2019","unstructured":"Takahashi, M. et al. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci. 110, 2247\u20132257. https:\/\/doi.org\/10.1111\/cas.14067 (2019).","journal-title":"Cancer Sci."},{"key":"35811_CR15","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.1038\/s41388-020-01404-x","volume":"39","author":"T Maeda","year":"2020","unstructured":"Maeda, T., Kitamura, S., Nishihara, H. & Yanagi, T. Extramammary Paget\u2019s disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies. Oncogene 39, 5867\u20135875. https:\/\/doi.org\/10.1038\/s41388-020-01404-x (2020).","journal-title":"Oncogene"},{"key":"35811_CR16","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo, M. et al. Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 4, 998\u20131013. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0001 (2014).","journal-title":"Cancer Discov."},{"key":"35811_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/cells8050418","volume":"8","author":"Y Koga","year":"2019","unstructured":"Koga, Y. & Ochiai, A. Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors. Cells 8, 418 (2019).","journal-title":"Cells"},{"key":"35811_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253\u2013265. https:\/\/doi.org\/10.1038\/nrc1317 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"35811_CR19","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","volume":"21","author":"NF Dybdal-Hargreaves","year":"2015","unstructured":"Dybdal-Hargreaves, N. F., Risinger, A. L. & Mooberry, S. L. Eribulin mesylate: Mechanism of action of a unique microtubule-targeting agent. Clin. Cancer Res. 21, 2445\u20132452. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3252 (2015).","journal-title":"Clin. Cancer Res."},{"key":"35811_CR20","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1158\/1078-0432.CCR-20-0232","volume":"27","author":"A Bernat-Peguera","year":"2021","unstructured":"Bernat-Peguera, A. et al. FGFR inhibition overcomes resistance to EGFR-targeted therapy in epithelial-like cutaneous carcinoma. Clin. Cancer Res. 27, 1491\u20131504. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0232 (2021).","journal-title":"Clin. Cancer Res."},{"key":"35811_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338\u2013350. https:\/\/doi.org\/10.1038\/nrclinonc.2012.61 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"35811_CR22","doi-asserted-by":"publisher","first-page":"50252","DOI":"10.18632\/oncotarget.17225","volume":"8","author":"BK Rajendran","year":"2017","unstructured":"Rajendran, B. K. & Deng, C. X. Characterization of potential driver mutations involved in human breast cancer by computational approaches. Oncotarget 8, 50252\u201350272. https:\/\/doi.org\/10.18632\/oncotarget.17225 (2017).","journal-title":"Oncotarget"},{"key":"35811_CR23","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","volume":"29","author":"E Maubec","year":"2011","unstructured":"Maubec, E. et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J. Clin. Oncol. 29, 3419\u20133426. https:\/\/doi.org\/10.1200\/JCO.2010.34.1735 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"35811_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jdv.17400","volume":"36","author":"K Peris","year":"2022","unstructured":"Peris, K., Piccerillo, A., Del Regno, L. & Di Stefani, A. Treatment approaches of advanced cutaneous squamous cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 36(Suppl 1), 19\u201322. https:\/\/doi.org\/10.1111\/jdv.17400 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"35811_CR25","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.3390\/cancers13225645","volume":"13","author":"AA Thai","year":"2021","unstructured":"Thai, A. A., Lim, A. M., Solomon, B. J. & Rischin, D. Biology and treatment advances in cutaneous squamous cell carcinoma. Cancers 13, 5645 (2021).","journal-title":"Cancers"},{"key":"35811_CR26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"C Twelves","year":"2014","unstructured":"Twelves, C. et al. Efficacy of eribulin in women with metastatic breast cancer: A pooled analysis of two phase 3 studies. Breast Cancer Res. Treat 148, 553\u2013561. https:\/\/doi.org\/10.1007\/s10549-014-3144-y (2014).","journal-title":"Breast Cancer Res. Treat"},{"key":"35811_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2020.01.008","volume":"128","author":"AJ Stratigos","year":"2020","unstructured":"Stratigos, A. J. et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur. J. Cancer 128, 83\u2013102. https:\/\/doi.org\/10.1016\/j.ejca.2020.01.008 (2020).","journal-title":"Eur. J. Cancer"},{"key":"35811_CR28","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.6004\/jnccn.2021.0059","volume":"19","author":"CD Schmults","year":"2021","unstructured":"Schmults, C. D. et al. NCCN guidelines(R) insights: Squamous cell skin cancer, version 1.2022. J. Natl. Compr. Cancer Netw. 19, 1382\u20131394. https:\/\/doi.org\/10.6004\/jnccn.2021.0059 (2021).","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"Suppl 8","key":"35811_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jdv.16024","volume":"33","author":"FF Gellrich","year":"2019","unstructured":"Gellrich, F. F. et al. Medical treatment of advanced cutaneous squamous-cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 33(Suppl 8), 38\u201343. https:\/\/doi.org\/10.1111\/jdv.16024 (2019).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"35811_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","volume":"81","author":"U Swami","year":"2012","unstructured":"Swami, U., Chaudhary, I., Ghalib, M. H. & Goel, S. Eribulin\u2014A review of preclinical and clinical studies. Crit. Rev. Oncol. Hematol. 81, 163\u2013184. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.03.002 (2012).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"35811_CR31","first-page":"1013","volume":"61","author":"MJ Towle","year":"2001","unstructured":"Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013\u20131021 (2001).","journal-title":"Cancer Res."},{"key":"35811_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00280-017-3369-7","volume":"80","author":"M Sugawara","year":"2017","unstructured":"Sugawara, M. et al. Eribulin shows high concentration and long retention in xenograft tumor tissues. Cancer Chemother. Pharmacol. 80, 377\u2013384. https:\/\/doi.org\/10.1007\/s00280-017-3369-7 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"35811_CR33","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan, M. A. et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4, 1086\u20131095. https:\/\/doi.org\/10.1158\/1535-7163.MCT-04-0345 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"35811_CR34","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2174\/156800907783220417","volume":"7","author":"MA Jordan","year":"2007","unstructured":"Jordan, M. A. & Kamath, K. How do microtubule-targeted drugs work? An overview. Curr. Cancer Drug Targets 7, 730\u2013742. https:\/\/doi.org\/10.2174\/156800907783220417 (2007).","journal-title":"Curr. Cancer Drug Targets"},{"key":"35811_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/BTT.S19811","volume":"6","author":"S Jain","year":"2012","unstructured":"Jain, S. & Cigler, T. Eribulin mesylate in the treatment of metastatic breast cancer. Biologics 6, 21\u201329. https:\/\/doi.org\/10.2147\/BTT.S19811 (2012).","journal-title":"Biologics"},{"key":"35811_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-022-00505-x","author":"P Shukla","year":"2022","unstructured":"Shukla, P. et al. ARID2 suppression promotes tumor progression and upregulates cytokeratin 8, 18 and \u03b2-4 integrin expression in TP53-mutated tobacco-related oral cancer and has prognostic implications. Cancer Gene Ther. https:\/\/doi.org\/10.1038\/s41417-022-00505-x (2022).","journal-title":"Cancer Gene Ther."},{"key":"35811_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/cancers10090288","volume":"10","author":"M Vieler","year":"2018","unstructured":"Vieler, M. & Sanyal, S. p53 isoforms and their implications in cancer. Cancers 10, 288 (2018).","journal-title":"Cancers"},{"key":"35811_CR38","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/ijc.27900","volume":"132","author":"G Manceau","year":"2013","unstructured":"Manceau, G. et al. Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. Int. J. Cancer 132, 2217\u20132221. https:\/\/doi.org\/10.1002\/ijc.27900 (2013).","journal-title":"Int. J. Cancer"},{"key":"35811_CR39","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1038\/ncomms3873","volume":"4","author":"India Project Team of the International Cancer Genome, C","year":"2013","unstructured":"India Project Team of the International Cancer Genome, C. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat. Commun. 4, 2873. https:\/\/doi.org\/10.1038\/ncomms3873 (2013).","journal-title":"Nat. Commun."},{"key":"35811_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/ijc.28705","volume":"135","author":"T Cajuso","year":"2014","unstructured":"Cajuso, T. et al. Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. Int. J. Cancer 135, 611\u2013623. https:\/\/doi.org\/10.1002\/ijc.28705 (2014).","journal-title":"Int. J. Cancer"},{"key":"35811_CR41","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/cancers13184507","volume":"13","author":"M Piipponen","year":"2021","unstructured":"Piipponen, M., Riihil\u00e4, P., Nissinen, L. & K\u00e4h\u00e4ri, V.-M. The role of p53 in progression of cutaneous squamous cell carcinoma. Cancers 13, 4507 (2021).","journal-title":"Cancers"},{"key":"35811_CR42","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1038\/jid.2014.154","volume":"134","author":"AP South","year":"2014","unstructured":"South, A. P. et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J. Investig. Dermatol. 134, 2630\u20132638. https:\/\/doi.org\/10.1038\/jid.2014.154 (2014).","journal-title":"J. Investig. Dermatol."},{"key":"35811_CR43","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/cncr.30459","volume":"123","author":"AS Yilmaz","year":"2017","unstructured":"Yilmaz, A. S. et al. Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors. Cancer 123, 1184\u20131193. https:\/\/doi.org\/10.1002\/cncr.30459 (2017).","journal-title":"Cancer"},{"key":"35811_CR44","doi-asserted-by":"publisher","first-page":"8493","DOI":"10.1073\/pnas.92.18.8493","volume":"92","author":"ML Agarwal","year":"1995","unstructured":"Agarwal, M. L., Agarwal, A., Taylor, W. R. & Stark, G. R. p53 controls both the G2\/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 92, 8493\u20138497. https:\/\/doi.org\/10.1073\/pnas.92.18.8493 (1995).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"35811_CR45","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.22034\/APJCP.2017.18.10.2679","volume":"18","author":"LP Das","year":"2017","unstructured":"Das, L. P. et al. Analysis of ARID2 gene mutation in oral squamous cell carcinoma. Asian Pac. J. Cancer Prev. 18, 2679\u20132681. https:\/\/doi.org\/10.22034\/APJCP.2017.18.10.2679 (2017).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"35811_CR46","doi-asserted-by":"publisher","first-page":"45863","DOI":"10.18632\/oncotarget.10244","volume":"7","author":"Y Duan","year":"2016","unstructured":"Duan, Y. et al. Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression. Oncotarget 7, 45863\u201345875. https:\/\/doi.org\/10.18632\/oncotarget.10244 (2016).","journal-title":"Oncotarget"},{"key":"35811_CR47","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1073\/pnas.1914937117","volume":"117","author":"H Jiang","year":"2020","unstructured":"Jiang, H. et al. Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. Proc. Natl. Acad. Sci. U. S. A. 117, 4770\u20134780. https:\/\/doi.org\/10.1073\/pnas.1914937117 (2020).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"35811_CR48","doi-asserted-by":"publisher","first-page":"109696","DOI":"10.1016\/j.biopha.2019.109696","volume":"122","author":"M Wu","year":"2020","unstructured":"Wu, M. et al. MiR-155\u20135p promotes oral cancer progression by targeting chromatin remodeling gene ARID2. Biomed. Pharmacother. 122, 109696. https:\/\/doi.org\/10.1016\/j.biopha.2019.109696 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"35811_CR49","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1038\/s41598-018-25669-1","volume":"8","author":"M Simbolo","year":"2018","unstructured":"Simbolo, M. et al. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci. Rep. 8, 7119. https:\/\/doi.org\/10.1038\/s41598-018-25669-1 (2018).","journal-title":"Sci. Rep."},{"key":"35811_CR50","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.18632\/aging.202489","volume":"13","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Expression and prognostic values of ARID family members in breast cancer. Aging (Albany NY) 13, 5621\u20135637. https:\/\/doi.org\/10.18632\/aging.202489 (2021).","journal-title":"Aging (Albany NY)"},{"key":"35811_CR51","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1038\/s41388-021-01748-y","volume":"40","author":"T Moreno","year":"2021","unstructured":"Moreno, T. et al. ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer. Oncogene 40, 2923\u20132935. https:\/\/doi.org\/10.1038\/s41388-021-01748-y (2021).","journal-title":"Oncogene"},{"key":"35811_CR52","unstructured":"Institute, S. Cell Model Passports. https:\/\/cellmodelpassports.sanger.ac.uk\/."},{"key":"35811_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s0165-6147(03)00026-9","volume":"24","author":"ZA Stewart","year":"2003","unstructured":"Stewart, Z. A., Westfall, M. D. & Pietenpol, J. A. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 24, 139\u2013145. https:\/\/doi.org\/10.1016\/s0165-6147(03)00026-9 (2003).","journal-title":"Trends Pharmacol. Sci."},{"key":"35811_CR54","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1136\/gutjnl-2017-315201","volume":"67","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut 67, 1845\u20131854. https:\/\/doi.org\/10.1136\/gutjnl-2017-315201 (2018).","journal-title":"Gut"},{"key":"35811_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-019-0518-z","volume":"7","author":"A Capasso","year":"2019","unstructured":"Capasso, A. et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J. Immunother. Cancer 7, 37. https:\/\/doi.org\/10.1186\/s40425-019-0518-z (2019).","journal-title":"J. Immunother. Cancer"},{"key":"35811_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF02621233","volume":"22","author":"M Rosdy","year":"1986","unstructured":"Rosdy, M., Bernard, B. A., Schmidt, R. & Darmon, M. Incomplete epidermal differentiation of A431 epidermoid carcinoma cells. In Vitro Cell. Dev. Biol. 22, 295\u2013300. https:\/\/doi.org\/10.1007\/BF02621233 (1986).","journal-title":"In Vitro Cell. Dev. Biol."},{"key":"35811_CR57","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1046\/j.0022-202x.2001.01431.x","volume":"117","author":"T Inoue","year":"2001","unstructured":"Inoue, T., Toda, S., Narisawa, Y. & Sugihara, H. Subcutaneous adipocytes promote the differentiation of squamous cell carcinoma cell line (DJM-1) in collagen gel matrix culture. J. Investig. Dermatol. 117, 244\u2013250. https:\/\/doi.org\/10.1046\/j.0022-202x.2001.01431.x (2001).","journal-title":"J. Investig. Dermatol."},{"key":"35811_CR58","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jdermsci.2017.08.004","volume":"88","author":"S Kitamura","year":"2017","unstructured":"Kitamura, S. et al. Drp1 regulates mitochondrial morphology and cell proliferation in cutaneous squamous cell carcinoma. J. Dermatol. Sci. 88, 298\u2013307. https:\/\/doi.org\/10.1016\/j.jdermsci.2017.08.004 (2017).","journal-title":"J. Dermatol. Sci."},{"key":"35811_CR59","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1158\/0008-5472.CAN-14-0872","volume":"74","author":"T Yanagi","year":"2014","unstructured":"Yanagi, T., Krajewska, M., Matsuzawa, S. & Reed, J. C. PCTAIRE1 phosphorylates p27 and regulates mitosis in cancer cells. Cancer Res. 74, 5795\u20135807. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0872 (2014).","journal-title":"Cancer Res."},{"key":"35811_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jdermsci.2017.02.281","volume":"86","author":"T Yanagi","year":"2017","unstructured":"Yanagi, T. et al. PCTAIRE1\/CDK16\/PCTK1 is overexpressed in cutaneous squamous cell carcinoma and regulates p27 stability and cell cycle. J. Dermatol. Sci. 86, 149\u2013157. https:\/\/doi.org\/10.1016\/j.jdermsci.2017.02.281 (2017).","journal-title":"J. Dermatol. Sci."},{"key":"35811_CR61","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41374-018-0042-7","volume":"98","author":"T Ivanics","year":"2018","unstructured":"Ivanics, T. et al. Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type. Lab. Investig. 98, 947\u2013956. https:\/\/doi.org\/10.1038\/s41374-018-0042-7 (2018).","journal-title":"Lab. Investig."},{"key":"35811_CR62","doi-asserted-by":"publisher","first-page":"8589","DOI":"10.3892\/ol.2018.8401","volume":"15","author":"D Lu","year":"2018","unstructured":"Lu, D. et al. Patient-derived tumor xenografts of lung squamous cell carcinoma alter long non-coding RNA profile but not responsiveness to cisplatin. Oncol. Lett. 15, 8589\u20138603. https:\/\/doi.org\/10.3892\/ol.2018.8401 (2018).","journal-title":"Oncol. Lett."},{"key":"35811_CR63","first-page":"1611","volume":"32","author":"MJ Towle","year":"2012","unstructured":"Towle, M. J. et al. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): Optimal effectiveness under intermittent dosing conditions. Anticancer Res. 32, 1611\u20131619 (2012).","journal-title":"Anticancer Res."},{"key":"35811_CR64","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-18-1495","volume":"78","author":"T Yanagi","year":"2018","unstructured":"Yanagi, T. et al. Loss of TRIM29 alters keratin distribution to promote cell invasion in squamous cell carcinoma. Cancer Res. 78, 6795\u20136806. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1495 (2018).","journal-title":"Cancer Res."},{"key":"35811_CR65","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.CAN-06-0594","volume":"67","author":"V Dangles-Marie","year":"2007","unstructured":"Dangles-Marie, V. et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: Comparison of success rate and cell line features. Cancer Res. 67, 398\u2013407. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0594 (2007).","journal-title":"Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35811-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35811-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35811-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T12:02:07Z","timestamp":1685188927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35811-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35811"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35811-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2531053\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,27]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8650"}}